Imunocare (Imiquimod)

Imiquimod activates Toll‑like receptor 7 on immune cells in the skin, leading to the release of cytokines such as interferon‑α and interleukin‑12. These signaling molecules boost both innate and adaptive immunity, targeting viral particles and early cancer cells within the treated area.

The specific dosing regimen for Imunocare is determined by the prescribing clinician based on the indication, lesion size, and patient factors. Healthcare providers set the amount, frequency, and duration of application according to approved guidelines.

Safety data for Imunocare in pregnancy and lactation are limited. It is classified as a precautionary medication, and use is generally avoided unless the potential benefit justifies the possible risk to the fetus or infant.

To place an order, submit an enquiry on the Imunocare product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with alternatives such as 5‑fluorouracil or podophyllotoxin, Imunocare offers a mechanism based on immune activation rather than direct cytotoxicity. This can result in a different side‑effect profile, often with more localized skin reactions but fewer systemic toxicities.

Imunocare should be stored at room temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed when not in use.

The medication is applied topically to the affected area using a fingertip or applicator, as directed by the prescriber. Typically, a thin layer is spread over the lesion once daily or as instructed, and the treated skin is left uncovered for the prescribed period.

Serious adverse events, although rare, include severe allergic reactions such as angioedema, extensive ulceration or necrosis of the skin, systemic flu‑like symptoms, and secondary bacterial infection of the treated site. Patients should seek medical attention promptly if these occur.

Imunocare is contraindicated in individuals with known hypersensitivity to imiquimod or any formulation components. It should also be avoided in patients with active severe skin infections, uncontrolled autoimmune disorders, or those who are pregnant or breastfeeding unless the prescriber determines that the benefits outweigh the risks.